Incidence of cancer and overall risk of mortality in individuals treated with raltegravir ‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

ConclusionsWe found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.

Source: HIV Medicine - October 6, 2017 Category: Infectious Diseases Authors: A Cozzi ‐Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich, R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren, A Mocroft, Tags: Original Research Source Type: research